• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Ripalid
    / Perrigo

    Active Ingredient
    Repaglinide 0.5, 1, 2 mg

    Status in Israel

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft


    90 X 0.5 mg

    not in the basket chart 63286


    90 X 1 mg

    not in the basket chart 63287


    90 X 2 mg

    not in the basket chart 63288

    Related information


    Usually initial dose is 0.5 mg, 30 min. before each main meal, with a glass of water. Dose may be increased up to 16 mg a day according to patient needs.
    Please refer to the license holder for further details.


    Repaglinide is indicated in adults with type 2 diabetes mellitus whose hyperglycaemia can no longer be controlled satisfactorily by diet, weight reduction and exercise.
    Repaglinide is also indicated in combination with metformin in adults with type 2 diabetes mellitus who are not satisfactorily controlled on metformin alone.
    Treatment should be initiated as an adjunct to diet and exercise to lower the blood glucose in relation to meals.  


    Hypersensitivity to Active Substance or any of Its Excipients. Patients wth type 1 diabetes. Patients with diabetic ketoacidosis. Severe liver disease. Concomitant use with gemfibrozil.

    Rivopharm SA